XVIVO has decided to close the PrimECC(R) Study for Further Patient Inclusions - Strategic Opportunities will be Evaluated

GOTHENBURG, SE / ACCESSWIRE / July 12, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) PrimECC is a solution used to prime the heart-lung machine before heart-surgery. It is a CE-marked and patent-protected product and is developed to …